Beta-Defensin vs VIP
A side-by-side research comparison of Beta-Defensin and VIP across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Beta-Defensin | VIP |
|---|---|---|
| Full name | Human Beta-Defensin Peptides | Vasoactive Intestinal Peptide |
| Category | Immune Support | Immune Support |
| Status | Research compound | Research compound |
| Mechanism | Form pores in microbial membranes causing lysis, recruit immune cells via CCR6 receptor chemotaxis, and bridge innate and adaptive immunity by activating dendritic cells. | Activates VPAC1 and VPAC2 receptors, raising intracellular cAMP. This dampens pro-inflammatory cytokine production, supports vasodilation and pulmonary function, and modulates regulatory T-cell activity. |
| Molecular weight | 4000-5000 Da | ~3326 Da |
| Half-life | ~2-4 hours | Very short (~1-2 minutes in plasma) |
| Bioavailability | Primarily local/mucosal activity | Intranasal (most common in protocols); rapidly degraded systemically |
| Typical dose | 50-200 mcg | ~50 mcg per spray |
| Frequency | Daily or as needed | 1-4x daily |
| Route | Topical or subcutaneous | Intranasal spray |
Beta-Defensin reported benefits
- Broad antimicrobial activity
- Immune cell recruitment
- Wound healing support
- Biofilm disruption
VIP reported benefits
- Broad anti-inflammatory effect
- Supports pulmonary and vascular function
- Immune modulation (regulatory T cells)
- Used in chronic inflammatory response protocols
Related comparisons
Research and educational reference only. Not medical advice.